Roth Capital Initiates Buy on Apellis Pharmaceuticals with $31 Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy APLS?
Source: seekingalpha
- Market Reaction Analysis: Despite a ~75% decline from its 2023 peak, Roth Capital Partners views Apellis Pharmaceuticals (APLS) as a compelling investment opportunity due to its lead asset, Syfovre, indicating market recognition of its potential.
- Stable Market Share: Analyst Adam Walsh notes that Syfovre holds about a 60% market share in geographic atrophy (GA), with injection volumes increasing by 17% in FY25, demonstrating the company's strong competitive position in this sector.
- Revenue Forecast Upgrade: Walsh projects that with accelerated adoption of Syfovre starting in FY27, particularly due to the launch of a prefilled syringe and functional imaging tools, the company's revenue will exceed market expectations, highlighting future growth potential.
- Long-term Revenue Projection: The analyst estimates that peak revenue for Syfovre could reach $1.2 billion by FY34, which is 30% above consensus, indicating significant financial growth prospects for the company in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Acquires Apellis to Strengthen Immunology Position
- Acquisition Details: Biogen has agreed to acquire Apellis for $41 per share in cash, valuing the deal at approximately $5.6 billion, which is expected to enhance Biogen's market position in immunology and rare diseases while providing immediate revenue.
- Expanded Drug Portfolio: The acquisition adds two commercial medicines, EMPAVELI and SYFOVRE, to Biogen's portfolio, with projected combined net sales of $689 million by 2025 and a mid-to-high teens growth rate through at least 2028, significantly improving the company's long-term growth outlook.
- Significant Clinical Outcomes: EMPAVELI is the only FDA-approved treatment for C3G, demonstrating a 68% reduction in proteinuria in the VALIANT study, while SYFOVRE has shown substantial reductions in GA lesion growth in the OAKS and DERBY studies, further solidifying Biogen's expansion in nephrology.
- Future Outlook and Employee Integration: Biogen expects to integrate a significant portion of Apellis employees post-transaction, with plans to close the deal in Q2 2026, further enhancing the company's capabilities in treating kidney diseases with the anticipated launch of Felzartamab.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Deal: Biogen announced on Tuesday its acquisition of Apellis Pharmaceuticals for $5.6 billion, significantly enhancing its drug pipeline by adding two approved drugs, thereby solidifying its market position in the biopharmaceutical sector.
- Pipeline Expansion: This acquisition will introduce two approved drugs into Biogen's product portfolio, which is expected to provide robust support for the company's future revenue growth, particularly in applications within the neuroscience field.
- Strategic Market Shift: By acquiring Apellis, Biogen not only boosts its competitiveness in the biopharmaceutical market but also aims to optimize R&D efficiency through the integration of Apellis's technologies and resources, fostering the development of innovative drugs.
- Financial Impact: The transaction is expected to positively affect Biogen's financial status; although the acquisition cost is substantial at $5.6 billion, the anticipated market sales from the new drugs are expected to yield significant returns on investment.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Ademi LLP Investigates Apellis for Fiduciary Breaches
- Investigation Launched: Ademi LLP is investigating Apellis (NASDAQ:APLS) for potential breaches of fiduciary duty and other legal violations in its transaction with Biogen, highlighting concerns over corporate governance.
- Shareholder Benefit Structure: In the transaction, Apellis shareholders will receive $41 per share plus contingent value rights, with additional payments tied to SYFOVRE's sales performance, indicating a reliance on future revenue targets.
- Competition Restriction Clause: The transaction agreement imposes significant penalties on Apellis for accepting competing bids, potentially harming shareholder interests and raising legal disputes regarding the board's fiduciary duties.
- Internal Conflicts of Interest: Apellis insiders stand to gain substantial benefits from change of control arrangements, raising questions about whether the board is fulfilling its fiduciary responsibilities to all shareholders.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Biogen Acquires Apellis to Strengthen Immunology Position
- Acquisition Details: Biogen has agreed to acquire Apellis for $41 per share in cash, valuing the deal at approximately $5.6 billion, which is expected to enhance Biogen's market position in immunology and rare diseases while providing immediate revenue.
- Expanded Drug Portfolio: The acquisition adds two commercial medicines, EMPAVELI and SYFOVRE, to Biogen's portfolio, with projected combined net sales of $689 million by 2025 and a mid-to-high teens growth rate through at least 2028, significantly improving the company's long-term growth outlook.
- Significant Clinical Outcomes: EMPAVELI is the only FDA-approved treatment for C3G, demonstrating a 68% reduction in proteinuria in the VALIANT study, while SYFOVRE has shown substantial reductions in GA lesion growth in the OAKS and DERBY studies, further solidifying Biogen's expansion in nephrology.
- Future Outlook and Employee Integration: Biogen expects to integrate a significant portion of Apellis employees post-transaction, with plans to close the deal in Q2 2026, further enhancing the company's capabilities in treating kidney diseases with the anticipated launch of Felzartamab.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Deal: Biogen announced on Tuesday its acquisition of Apellis Pharmaceuticals for $5.6 billion, significantly enhancing its drug pipeline by adding two approved drugs, thereby solidifying its market position in the biopharmaceutical sector.
- Pipeline Expansion: This acquisition will introduce two approved drugs into Biogen's product portfolio, which is expected to provide robust support for the company's future revenue growth, particularly in applications within the neuroscience field.
- Strategic Market Shift: By acquiring Apellis, Biogen not only boosts its competitiveness in the biopharmaceutical market but also aims to optimize R&D efficiency through the integration of Apellis's technologies and resources, fostering the development of innovative drugs.
- Financial Impact: The transaction is expected to positively affect Biogen's financial status; although the acquisition cost is substantial at $5.6 billion, the anticipated market sales from the new drugs are expected to yield significant returns on investment.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Ademi LLP Investigates Apellis for Fiduciary Breaches
- Investigation Launched: Ademi LLP is investigating Apellis (NASDAQ:APLS) for potential breaches of fiduciary duty and other legal violations in its transaction with Biogen, highlighting concerns over corporate governance.
- Shareholder Benefit Structure: In the transaction, Apellis shareholders will receive $41 per share plus contingent value rights, with additional payments tied to SYFOVRE's sales performance, indicating a reliance on future revenue targets.
- Competition Restriction Clause: The transaction agreement imposes significant penalties on Apellis for accepting competing bids, potentially harming shareholder interests and raising legal disputes regarding the board's fiduciary duties.
- Internal Conflicts of Interest: Apellis insiders stand to gain substantial benefits from change of control arrangements, raising questions about whether the board is fulfilling its fiduciary responsibilities to all shareholders.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
